Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Humana Inc (HUM) vs MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) Price & Performance

Humana IncTrade
MONDELEZ INTERNATIONAL INC Common StockTrade

Price performance (Past 24H)

Key statistics

Humana Inc vs MONDELEZ INTERNATIONAL INC Common Stock — how do they compare? Humana Inc trades at $374.25 (market cap $46.31B), while MONDELEZ INTERNATIONAL INC Common Stock trades at $61.73 (market cap $79.91B). The key difference: MONDELEZ INTERNATIONAL INC Common Stock is the larger of the two by market cap, and MONDELEZ INTERNATIONAL INC Common Stock pays the higher dividend (3.19%). Which is the better fit depends on your goals.

HUMMDLZ
Market Cap
$46.31B$79.91B
Sector
HealthConsumer Staples
52-Week High
$409.42$64.99
52-Week Low
$163.67$51.51
Enterprise Value
$53.67B$100.25B
Dividend Yield
0.92%3.19%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Humana Inc

Humana (HUM) trades at $385.00, up 4.82% today, with a bullish technical outlook and analyst consensus price target of $399.53. Recent earnings beats in Q1 and Q2 2026, alongside revenue growth to $129.66 billion in 2025, support fundamentals, though net margins have compressed. The company is expanding its Medicaid business and targeting margin improvements by 2027.

The stock offers upside to consensus targets but faces risks from Medicare Advantage margin pressures and regulatory changes. Profitability trends are weak despite revenue growth, requiring successful cost management to meet 2028 targets. Institutional sentiment is mixed with a majority hold rating.

MONDELEZ INTERNATIONAL INC Common Stock

MDLZ trades at $62.61, down 0.22% on the day, with a bullish technical signal from moving averages and RSI near oversold levels. Recent Q2 2026 earnings beat estimates with EPS of $0.73 versus $0.68 expected, driven by 2.2% organic revenue growth. The company raised its 2026 organic sales outlook, supported by strength in emerging markets and improved execution in North America. Cash flow from operations remains robust at $4.5 billion in 2025, though net income margin dipped to 6.36% from higher costs.

Outlook is positive with a consensus price target of $70.50, implying 12.6% upside, and 76% of analysts rate it a buy. Risks include reliance on international sales exposure to currency fluctuations and competitive pressures in the snack industry. Valuation multiples like P/E of 38.25 appear elevated relative to historical norms, requiring sustained earnings growth to justify current levels.

Returns comparison

Trailing returns across standard periods

About Humana Inc

Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.

Read more on HUM

About MONDELEZ INTERNATIONAL INC Common Stock

Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.

Read more on MDLZ